Response to 'considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma'

Cancer Treat Rev. 2022 Dec:111:102478. doi: 10.1016/j.ctrv.2022.102478. Epub 2022 Oct 22.

¹ Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
² Institut Universitaire du Cancer et CHU de Toulouse, Toulouse, France; Inserm UMR 1037 - CRCT, Toulouse, France.
³ Clinica Oncologica, AOU Ospedali Riuniti, Ancona, Università Politecnica delle Marche, Ancona, Italy.
⁴ Experimental and Clinical Oncology of Immunotherapy and Rare Tumors, IRCCS IRST "Dino Amadori", Meldola, FC, Italy.
⁵ IQVIA, London, UK.
⁶ IQVIA, Athens, Greece.
⁷ Aix-Marseille Université, Marseille, France; Pierre Fabre Laboratories, Paris, France.
⁸ Aix-Marseille Université, Marseille, France; Pierre Fabre Laboratories, Paris, France. Electronic address: philippe.laramee@pierre-fabre.com.

No abstract available

Publication types